Back to News
Market Impact: 0.35
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Source: PR Newswire
Corporate EarningsCompany FundamentalsCurrency & FX
Revenue was RMB 11.8B, up 18.4% YoY (23.4% YoY in USD), while IFRS gross margin rose 350 bps to 46.2% and adjusted gross margin increased 280 bps to 48.4%. Despite foreign-exchange headwinds, EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY, indicating improving profitability but slower bottom-line growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Why is T-Mobile stock tumbling today?
- Why is Verizon stock sliding today?
- SpaceX wants to become a 'major mobile carrier' with low-band spectrum acquisition
- OpenAI projected to bring in $20bn less in revenue than expected
- Soitec climbs 7% as BofA turns bullish on silicon photonics demand
- Schott Pharma drops after Deutsche Bank downgrades on demanding valuation